• Prescribing Information
• Indication and Important Safety Considerations
• Site Map
• Register for Updates

• Home
• About ZOMIG
  • Fast Headache Response
  • Pain-free Response
  • Formulation Options
  • Prescribing Information
• HCP Resources
• Resources for Your Patients
• ZOMIG Virtual Rep

Choose the ZOMIG formulation best suited for your patient.

ZOMIG (zolmitriptan) is available in 3 formulations—ZOMIG® Tablets, ZOMIG–ZMT® (zolmitriptan) and ZOMIG® Nasal Spray–all providing fast and powerful migraine relief for today’s migraineur. With demanding lives full of family, work, and friends, your patients need migraine treatment options that can provide migraine relief as well as fit their busy lifestyles.

To help make a selection for your patient’s treatment program, compare your patient’s migraine experiences and preferences to the characteristics chart below.

That's versatility!

Indication and Important Safety Considerations

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.
ZOMIG is not intended for the prophylactic therapy of migraine and is not indicated for the treatment of cluster headache.
• ZOMIG is contraindicated in patients with
• -  Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
• -  Cerebrovascular syndromes (eg, history of stroke or TIA)
• -  Peripheral vascular disease (eg, ischemic bowel disease)
• -  Uncontrolled hypertension
• Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
• ZOMIG should not be administered to patients with hemiplegic or basilar migraine
• It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
• Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
• Development of potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) contains phenylalanine
• ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
• Most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
• Most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness